RxDoctor Payments Data

Eric Granowicz, MD

Hematology · Jackson, MINPI 1750776985

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Beigene USA, Inc. at 24.0% of the total. Reporting peaked in 2023 at $382 and has fallen 90.0% since, to $38 in 2025. That places this record below the midpoint for hematology clinicians in MI, where the typical reported total is $667.

$667in general payments, 2019–2025

Across 8 payments — averaging $83.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene USA, Inc.$160
  • Bristol Myers Squibb$125
  • Novo Nordisk$122
  • Seagen Inc.$116
  • Amgen$106
  • Beckman Coulter, Inc.$25
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$667 in reported general payments places this provider in the 50th percentile of 50 hematology providers in Michigan.

See all hematology providers in Michigan

Medicare billing

Part B allowed, 2024
$62,192
Medicare patients
172
Services billed
931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide21$403,294
BrukinsaZanubrutinib23$336,294
XtandiEnzalutamide20$274,097
TagrissoOsimertinib Mesylate11$181,859
Abiraterone Acetate27$22,089
EliquisApixaban33$19,029
Anastrozole60$1,994
Acyclovir30$344
Dexamethasone22$308
Tamoxifen Citrate21$301
Ondansetron OdtOndansetron11$214
Hydroxyurea11$181
Letrozole11$121
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$77
Prednisone17$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$125$403,29421 claims
Beigene USA, Inc.Brukinsa$160$336,29423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 50 hematology providers in Michigan.

Other hematology in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →